Cryospray Ablation of Surgical Resection Specimens To Determine Safety And Histological Effect In The Lung

PHASE4CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

June 30, 2008

Study Completion Date

August 31, 2008

Conditions
Lung Cancer
Interventions
DEVICE

CryoSpray Ablation System

"CSA Medical, Inc. (formerly CryMed Technologies, Inc.) received FDA market clearance for the CSA System (CryoSpray AblationTM System, formally Cryo Ablator System) on April 21, 2006. It is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications (K070893). As defined by the FDA, the CSA System is a cryosurgical unit with a liquid nitrogen cooled cryocatheter and accessories used to destroy tissue during surgical procedures by applying extreme cold"

Trial Locations (1)

21237

Franklin Square Hospital Center, Baltimore

Sponsors

Lead Sponsor

All Listed Sponsors
lead

CSA Medical, Inc.

INDUSTRY

NCT00747773 - Cryospray Ablation of Surgical Resection Specimens To Determine Safety And Histological Effect In The Lung | Biotech Hunter | Biotech Hunter